Clinical trials: HER2-positive Metastatic Breast Cancer
Her2 Positive Metastatic Breast Cancer
The Myocet/Lapatinib Study. ICORG 10-03, V5
This study is a Phase I/II open label, multi-centre trial. Patients with HER2+ve metastatic breast cancer, following disease progression during, or after, treatment with trastuzumab and taxanes, will be treated with Lapatinib…
- Trial name
- NCT01495884
- Testing
- non-pegylated liposomal doxorubicon (Myocet™), Lapatinib (Tyverb™)
- Where
- 10 sites in Ireland
- Volunteers
- 11 people
- Sponsor
- Cancer Trials Ireland
Metastatic Breast Cancer, HER2 Positive
Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
The purpose of the study is to investigate safety and efficiency of the triple combination of capecitabine, lapatinib and vinorelbine in patients with metastatic breast cancer.
- Conditions
- Metastatic Breast Cancer, HER2 Positive, First or Second Line Therapy, Failure or Contraindication of Trastuzumab Therapy
- Trial name
- CELAVIE (NCT01238029)
- Testing
- Lapatinib and Capecitabine and Vinorelbine
- Where
- 11 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Sponsor GmbH
Central Nervous System Metastases, HER2-positive Breast Cancer
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. This phase II trial is studying how well lapatinib works in treating brain metastases in patients with stage IV breast cancer…
- Conditions
- Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00098605
- Testing
- lapatinib ditosylate, laboratory biomarker analysis, quality-of-life assessment
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, HER2 Positive Breast Cancer
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer
- Conditions
- Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
- Trial name
- NCT00817362
- Testing
- IPI-504, Trastuzumab
- Where
- 11 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Metastatic Breast Cancer, Brain Metastases
Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer
Objectives: Primary - Determine the maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLT) of combining lapatinib and temozolomideSecondary - Obtain preliminary information on the clinical anti-tumor…
- Conditions
- Metastatic Breast Cancer, Brain Metastases, HER2 Positive
- Trial name
- LAPTEM (NCT00614978)
- Testing
- lapatinib and temozolomide
- Where
- Belgium
- Volunteers
- 18 people
- Sponsor
- Jules Bordet Institute